Secuencia óptima del tratamiento del CCRm: ¿Cuál es el papel del panitumumab?.

10 / 31

Weight is relative weight (%) from the fixed effect model.
(n = 526)
(n = 342)
(n = 170)
1.10
(0.90−1.30)
0.93
(0.74−1.17)
0.65
(0.44−0.96)
0.98
(0.85−1.12)
0.92
(0.71−1.18)
0.0953
−0.073
−0.431
0.0938
0.199
53.6
34.5
11.9
100
0.1169
Heterogeneity: Chi2 = 5.97, df = 2, (P = 0.05), I2 = 66%, Tau2 = 0.03
CALGB
FIRE-3
PEAK
Total
Total
(fixed)
(random)
HR (95% CI) logHR logSE Weight
0.1 1 10
WT RAS
Favours anti-EGFR + CTx Favours bevacizumab + CTx
Disease Free Survival
Heinemann V, et al. Ann Oncol 2015.